Moderna, Merck Cancer Vaccine Development

Moderna and Merck have achieved a major breakthrough in cancer vaccine development, with their mRNA-based vaccine successfully preventing melanoma recurrence in late-stage trials. This represents a significant milestone in the decades-long effort to harness vaccine technology to train the immune system to identify and eliminate cancer cells. The advancement offers renewed hope for the mRNA vaccine platform despite previous setbacks and public skepticism.